Inflammatory Bowel Disease References

Last updated: 11 November 2024
  1. Carter MJ, Lobo AJ, Travis SPL; IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004 Sep;53(Suppl 5):v1-16. PMID: 15306569
  2. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012 Dec;6(10):965-990. doi: 10.1016/j.crohns.2012.09.003. PMID: 23040452
  3. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012 Dec;6(10):991-1030. http://www.ncbi.nlm.nih.gov. PMID: 23040451
  4. Feldman PA, Wolfson D, Barkin JS. Medical management of Crohn's disease. Clin Colon Rectal Surg. 2007 Nov;20(4):269-281. doi: 10.1055/s-2007-991026. PMID: 20011423
  5. Knutson D, Greenberg G, Cronau H. Management of Crohn's disease - a practical approach. Am Fam Physician. 2003 Aug;68(4):704-714. http://www.ncbi.nlm.nih.gov/pubmed/?term=12952387. PMID: 12952387
  6. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 2001 Mar;96(3):635-643. http://www.ncbi.nlm.nih.gov/pubmed/11280528. PMID: 11280528
  7. Kumar R, Singh J. The emerging therapy with prebiotics in the management of inflammatory bowel disease: current status. Int J Basic Clin Pharmacol. 2013;2(4):360-367. http://www.ijbcp.com/Volume2Issue4/IJBCP20130803.pdf. Accessed 25 Sep 2013
  8. Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010 Mar;105(3):501-523. http://gi.org/guideline/ulcerative-colitis-in-adults/. PMID: 20068560
  9. Leighton JA, Shen B, Baron TH, et al; Standards of Practice Committee, American Society for Gastrointestinal Endoscopy. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006 Apr;63(4):558-565. PMID: 16564852
  10. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar;130(3):940-987. http://www.ncbi.nlm.nih.gov/pubmed/?term=American++Gastroenterology+Association++Institute++technical+reviw+on+corticosteroids%2C+immunomodulators%2C+and+infliximab+on+inflammatory+bowel+disease. PMID: 16530532
  11. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Jan 06, 2009. Am J Gastroenterol. 2009 Feb;104(2):465-483. http://www.ncbi.nlm.nih.gov/pubmed/?term=19174807. PMID: 19174807
  12. Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013 Aug;7(7):556-585. doi: 10.1016/j.crohns.2013.02.020. PMID: 23583097
  13. Mowat C, Cole A, Windsor A, et al; IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011 May;60(5):571-607. doi: 10.1136/gut.2010.224154. PMID: 21464096
  14. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002 Aug;347(6):417-429. http://www.ncbi.nlm.nih.gov/pubmed/12167685. PMID: 12167685
  15. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov;125(5):1508-1530. http://www.ncbi.nlm.nih.gov/pubmed/?term=14598268. PMID: 14598268
  16. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005 Jul;22(1):001-16. http://www.ncbi.nlm.nih.gov/pubmed/?term=15963074. PMID: 15963074
  17. Strong SA, Koltun WA, Hyman NH, Buie WD; Standards Practice Task Force of The American Society of Colon and Rectal Surgeons. Practice parameters for the surgical management of Crohn's disease. Dis Colon Rectum. 2007 Nov;50(11):1735-1746. https://www.ncbi.nlm.nih.gov/pubmed/17690937. PMID: 17690937
  18. Turner D, Travis SP, Griffiths AM, et al; European Crohn’s and Colitis Organization; Porto IBD Working Group, European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011 Apr;106(4):574-588. doi: 10.1038/ajg.2010.481. PMID: 21224839
  19. MedWormhttp://www.medworm.com/rss/index.php/Gastroenterology/17/http://www.medworm.com/rss/medicalfeeds/specialities/Gastroenterology.xml
  20. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  21. Peppercorn MA. Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults. UpToDate. http://www.uptodate.com/index. Feb 2011. Accessed 03 Jun 2011
  22. Chan J. A review on the management of Crohn's disease. US Pharmacist. http://www.uspharmacist.com. Jan 2007. Accessed 16 Jun 2011.
  23. Peppercorn MA, Odze RD. Colorectal cancer surveillance in inflammatory bowel disease. UpToDate. http://www.uptodate.com/index. Aug 2010. Accessed 28 Jul 2011.
  24. Peppercorn MA. Clinical manifestations, diagnosis and prognosis of ulcerative colitis in adults. UpToDate. http://www.uptodate.com/index. Jan 2011. Accessed 03 Jun 2011
  25. Crohn's disease. http://www.accessmedicine.com. 2004. Accessed 27 Apr 2005.
  26. National Institute for Health and Care Excellence. Crohn's disease: management in adults, children and young people. NICE. http://www.nice.org.uk. 2012. Accessed 10 Jul 2013.
  27. National Institute for Health and Care Excellence. Guidance on the use of infliximab for Crohn's disease. NICE. http://www.nice.org.uk. 2002. Accessed 30 Sep 2005
  28. Rowe WA. Inflammatory bowel disease. eMedicine. http://emedicine.medscape.com. Jun 2011. Accessed 18 Jul 2011
  29. National Guideline Clearinghouse (NGC). Guideline summary: practice parameters for the surgical treatment of ulcerative colitis. Agency for Healthcare, Research and Quality. http://www.guideline.gov. 18 Jul 2011.
  30. World Gastroenterology Organisation Global Guidelines. Inflammatory bowel disease: a global perspective. World Gastroenterology Organisation. http://www.worldgastroenterology.org. Jun 2009.
  31. National Institute for Health and Care Excellence. Infliximab (review) and adalimumab for the treatment of Crohn’s disease. NICE. http://www.nice.org.uk. 2011. Accessed 09 Jul 2013.
  32. Desimone EM, Lanspa SJ, Hogrefe D, et al. Management and treatment of Crohn's disease. US Pharmacist. http://www.uspharmacist.com. 2004. Accessed 27 Apr 2005.
  33. Peppercorn MA, Farrell RJ. Medical management of ulcerative colitis. UpToDate. http://www.uptodate.com/index. Nov 2010. Accessed 03 Jun 2011
  34. Farrell RJ, Peppercorn MA. Overview of the medical management of mild to moderate Crohn's disease in adults. UpToDate. http://www.uptodate.com/index. 27 Apr 2011. Accessed 03 Jun 2011
  35. Centers for Disease Control and Prevention. Inflammatory bowel disease. CDC. http://www.cdc.gov/ibd/. 14 Jan 2014.
  36. MacDermott RP. Management of mild to moderate ulcerative colitis. UpToDate. http://www.uptodate.com. 13 Feb 2013.
  37. Peppercorn MA, Kane SV. Patient information: ulcerative colitis (beyond the basics). UpToDate. http://www.uptodate.com. 18 Dec 2013.
  38. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014 Mar;63(3):433-441. doi: 10.1136/gutjnl-2012-304258. PMID: 23436336
  39. Bernstein C, Eliakim A, Fedail S, et al. Inflammatory bowel disease. World Gastroenterology Organisation. http://www.worldgastroenterology.org. Aug 2015. Accessed 06 May 2016.
  40. Peppercorn MA, Odze RD. Colorectal cancer surveillance in inflammatory bowel disease. UpToDate. http://www.uptodate.com. 18 Feb 2015. Accessed 28 Jun 2016.
  41. Peyrin-Biroulet L, Panes J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol. 2016 Mar 11;14(3):348-354. http://dx.doi.org/10.1016/j.cgh.2015.06.001. Accessed 28 Jun 2016
  42. Gomollón F, Dignass A, Annese V, et al. 3. European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017 Jan;11(1):3-25. doi: 10.1093/ecco-jcc/jjw168. PMID: 27660341
  43. Gionchetti P, Dignass A, Danese S, et al. 3. European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2016 Sep 22. doi: 10.1093/ecco-jcc/jjw169. PMID: 27660342
  44. Gastroenterological Society of Australia (GESA). Clinical update for general practitioners and physicians - inflammatory bowel disease. Updated 2018. GESA. http://www.gesa.org.au. 2018. Accessed 02 Aug 2019.
  45. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017 Jul;11(7):769-784. doi: 10.1093/ecco-jcc/jjx009. Accessed 02 Aug 2019. PMID: 28513805
  46. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019 Feb;13(2):144-164. doi: 10.1093/ecco-jcc/jjy113. Accessed 02 Aug 2019. PMID: 30137275
  47. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017 Jun;11(6):649-670. doi: 10.1093/ecco-jcc/jjx008. Accessed 02 Aug 2019. PMID: 28158501
  48. Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018 Mar;53(3):305-353. doi: 10.1007/s00535-018-1439-1. Accessed 02 Aug 2019. PMID: 29429045
  49. National Institute for Health and Care Excellence (NICE). Crohn’s disease: management. NICE. https://www.nice.org.uk. 3 May 2019. Accessed 02 Aug 2019.
  50. National Institute for Health and Care Excellence (NICE). Ustekinumab for moderately to severely active Crohn’s disease after previous treatment. NICE. https://www.nice.org.uk. 12 Jul 2017. Accessed 08 Aug 2019.
  51. National Institute for Health and Care Excellence (NICE). Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy. NICE. https://www.nice.org.uk. 26 Aug 2015. Accessed 08 Aug 2019.
  52. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus and implications. Gut. 2006 Jun;55(6):749-753. doi: 10.1136/gut.2005.082909. Accessed 07 Aug 2019. PMID: 16698746
  53. Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019 Mar;13(3):273-284. doi: 10.1093/ecco-jcc/jjy114. Accessed 02 Aug 2019. PMID: 30137278
  54. U.S. Food & Drug Administration (US FDA). Biosimilar product information. US FDA. https://www.fda.gov/. 24 Feb 2020. Accessed 28 Feb 2020.
  55. Feuerstein JD, Isaacs KL, Schneider Y, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020 Jan 13. pii: S0016-5085(20)30018-4. doi: 10.1053/j.gastro.2020.01.006. PMID: 31945371
  56. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. PMID: 29610508
  57. Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018 Aug;48(4):394-409. doi: 10.1111/apt.14852. Accessed 24 Mar 2020. PMID: 29920733
  58. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020 Jan 1;14(1):4-22. doi: 10.1093/ecco-jcc/jjz180. PMID: 31711158
  59. Sulz MC, Burri E, Michetti P, et al. Treatment algorithms for Crohn's disease. Digestion. 2020 Mar 13:1-15. doi: 10.1159/000506364. PMID: 32172251
  60. Dassopoulos T, Cohen R, Scherl E, et al. Identification, assessment and initial medical treatment of ulcerative colitis. Clinical care pathway. American Gastroenterological Association (AGA). https://gastro.org.
  61. Sandborn W, Binion D, Persley K, et al. AGA Institute guidelines for the identification, assessment and initial medical treatment in Crohn’s disease. Clinical decision support tool. American Gastroenterological Association (AGA). https://gastro.org. Accessed Accessed 08 Jan 2021.
  62. American Society for Gastrointestinal Endoscopy Standards of Practice Committee; Shergill AK, Lightdale JR, Bruining DH, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015 May;81(5):1101-21.e1-13. doi: 10.1016/j.gie.2014.10.030. PMID: 25800660
  63. Clarke WT, Feuerstein JD. Colorectal cancer surveillance in inflammatory bowel disease: practice guidelines and recent developments. World J Gastroenterol. 2019 Aug 14;25(30):4148-4157. doi: 10.3748/wjg.v25.i30.4148. Accessed 24 Nov 2021. PMID: 31435169
  64. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010 Feb;138(2):746-774. doi: 10.1053/j.gastro.2009.12.035. PMID: 20141809
  65. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021 Jun;160(7):2496-2508. doi: 10.1053/j.gastro.2021.04.022. PMID: 34051983
  66. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019 Mar;114(3):384-413. doi: 10.14309/ajg.0000000000000152. PMID: 30840605
  67. Sandborn WJ, Feagan BG, D'Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. PMID: 34587385
  68. Zeposia highlights of prescribing information. U.S. Food & Drug Administration. https://www.accessdata.fda.gov. May 2021.
  69. Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis. 2020 Feb;14(2):155-168. doi: 10.1093/ecco-jcc/jjz187. Accessed 18 Apr 2022. PMID: 31742338
  70. Bischoff SC, Escher J, Hébuterne X, et al. ESPEN practical guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr. 2020 Mar;39(3):632-653. doi: 10.1016/j.clnu.2019.11.002. PMID: 32029281
  71. De Simone B, Davies J, Chouillard E, et al. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg. 2021 May;16(1):23. doi: 10.1186/s13017-021-00362-3. PMID: 33971899
  72. Holubar SD, Lightner AL, Poylin V, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the surgical management of ulcerative colitis. Dis Colon Rectum. 2021 Jul;64(7):783-804. doi: 10.1097/DCR.0000000000002037. PMID: 33853087
  73. Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019 Feb;156(3):748-764. doi: 10.1053/j.gastro.2018.12.009. PMID: 30576644
  74. Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021 Jun;15(6):879-913. doi: 10.1093/ecco-jcc/jjab052. PMID: 33730753
  75. Lightner AL, Vogel JD, Carmichael JC, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the surgical management of Crohn’s disease. Dis Colon Rectum. 2020 Aug;63(8):1028-1052. doi: 10.1097/DCR.0000000000001716. PMID: 32692069
  76. Murthy SK, Feuerstein JD, Nguyen GC, et al. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology. 2021 Sep;161(3):1043-1051. doi: 10.1053/j.gastro.2021.05.063. Accessed 18 Apr 2022. PMID: 34416977
  77. Spinelli A, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohns Colitis. 2022 Feb;16(2):179-189. doi: 10.1093/ecco-jcc/jjab177. PMID: 34635910
  78. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): colorectal cancer screening. Version 1.2022. NCCN. https://www.nccn.org. 04 Mar 2022. Accessed 26 Apr 2022.
  79. Hibi T. Risankizumab for Crohn's disease. Lancet. 2022 May 28;399(10340):1992-1993. doi: 10.1016/S0140-6736(22)00628-6. PMID: 35644143
  80. U.S. Food & Drug Administration (US FDA). Abrilada highlights of prescribing information. US FDA. https://www.fda.gov/. Nov 2019. Accessed 18 Aug 2022.
  81. Cohen RD, Stein AC. Management of moderate to severe ulcerative colitis in adults. UpToDate. https://www.uptodate.com. 20 Sep 2023. Accessed 25 Jul 2023.
  82. Gaertner WB, Burgess PL, Davids JS, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. Dis Colon Rectum. 2022 Aug;65(8):964-985. doi: 10.1097/DCR.0000000000002473. PMID: 35732009
  83. Hashash JA, Regueiro M. Medical management of moderate to severe Crohn disease in adults. UpToDate. https://www.uptodate.com. 17 Oct 2023. Accessed 25 Jul 2023.
  84. Lee SH, Kwon JE, Cho ML. Immunological pathways of inflammatory bowel disease. Intest Res. 2018 Jan;16(1):26-42. doi: 10.5217/ir.2018.16.1.26. Accessed 25 Jul 2023. PMID: 29422795
  85. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Colorectal cancer screening. Version 1.2023. NCCN. https://www.nccn.org/. 17 May 2023.
  86. National Institute for Health Care and Excellence (NICE). Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn’s disease or adenomas. NICE. https://www.nice.org.uk/. 20 Sep 2022.
  87. Peppercorn MA, Cheifetz AS. Definitions, epidemiology, and risk factors for inflammatory bowel disease. UpToDate. https://www.uptodate.com. 10 Jul 2023.
  88. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022 Jan 28;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178. PMID: 34635919
  89. Rogler G, Biedermann L, Schari M. New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways. Swiss Med Wkly. 2018 Mar;148:w14599. doi: 10.4414/smw.2018.14599. PMID: 29566254
  90. Saez A, Herrero-Fernandez B, Gomez-Bris R, et al. Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci. 2023 Jan;24(2):1526. doi: 10.3390/ijms24021526. PMID: 36675038
  91. Shah J, Dutta U, Das A, et al. Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: a prospective study. JGH Open. 2020 Jun;4(3):382-386. doi: 10.1002/jgh3.12260. PMID: 32514441
  92. Singh S, Ananthakrishnan AN, Nguyen NH, et al. AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology. 2023 Mar;164(3):344-372. doi: 10.1053/j.gastro.2022.12.007. PMID: 36822736
  93. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. PMID: 33359090
  94. Gordon H, Biancone L, Fiorino G, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis. 2023 Jun;17(6):827-854. doi: 10.1093/ecco-jcc/jjac187. PMID: 36528797
  95. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease. Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. PMID: 31562236
  96. D’Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023 Jun;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. PMID: 37379135
  97. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomized, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023 Apr;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. PMID: 36871574
  98. Honap S, Agorogianni A, Colwill MJ, et al. JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol. 2023 Sep 14;15(1):59-69. doi: 10.1136/flgastro-2023-102400. PMID: 38487554